Imaging Biomarkers in Clinical Trials: Focus on Oncology

 Imaging biomarkers serve as important endpoints for clinical trials in the approval process for therapeutic drugs. Various criteria have been developed for objective interpretation of imaging studies. Additionally, there are emerging imaging techniques that have the potential for applications as surrogate endpoints for clinical trials. 
In this program, we will review the current practice of imaging biomarkers in clinical trials in oncology.

Additionally, we will highlight advanced imaging techniques that have potential as surrogate biomarkers.
The educational need addresses a combination of knowledge, competence, and performance gaps. Imaging techniques and read criteria continue to evolve, and it is important for investigators to keep current with the best practices. Also, these are not used in daily clinical practice so knowledge can only be obtained from courses such as this or by reading medical literature.

We believe that didactic lectures from leading experts on topics with Q&A sessions will most efficiently disseminate the knowledge regarding imaging biomarkers and advanced imaging techniques. The lectures will include case studies of previous clinical trials, discussing their successes and failures.